Skip to NavigationSkip to content

vCJD caution prompts Serono product withdrawal

Published on 24/10/03 at 05:00pm

Serono is to withdraw one of its hormone products from the UK after a case of variant Creutzfeldt-Jakob disease was confirmed in Italy, where the product is manufactured.

The Committee on Safety of Medicines advised the withdrawal of IVF treatment Metrodin High Purity only as a precautionary measure, and stressed no cases of vCJD transmitted via urine or urine products have been reported.

The CSM added that there are adequate supplies of alternative products and that other urine-derived products on the UK market are unaffected.

The move follows the Government's recent purchase of a US company to guarantee supplies of blood plasma free of vCJD.

The NHS no longer uses plasma from British blood donors because they have, in theory, been exposed to vCJD through the food chain.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches